CPK850 ( DrugBank: - )

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
90	網膜色素変性症	2

90. 網膜色素変性症

臨床試験数 : 147 / 薬物数 : 176 - (DrugBank : 43) / 標的遺伝子数 : 49 - 標的パスウェイ数 : 110

diseases per page:

Showing 1 to 2 of 2 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03374657 (ClinicalTrials.gov)	August 22, 2018	11/12/2017	A First-in-human, Proof of Concept Study of CPK850 in Patients With RLBP1 Retinitis Pigmentosa	An Open-label First-in-human Single Ascending Dose Study to Explore Safety, Tolerability and Efficac ...	Retinitis Pigmentosa	Biological: CPK850	Novartis Pharmaceuticals	NULL	Active, not recruiting	18 Years	70 Years	All	12	Phase 1/Phase 2	Sweden
2	EUCTR2016-002696-10-SE (EUCTR)	09/05/2018	21/12/2017	Explore the safety and efficacy of subretinal administration of CPK850gene therapy in patients with ...	An open-label first-in-human single ascending dose study to explore the safety, tolerability and eff ...	retinitis pigmentosa caused by biallelic mutations in the RLBP1 gene MedDRA version: 20.0;Level: PT; ...	Product Code: CPK850 INN or Proposed INN: TBD	Novartis Pharma AG	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	21	Phase 1;Phase 2	Sweden

First Previous1Next Last